Trastuzumab: all 614 studies that test it
Page 1 of 7. Open to participants first (88), then studies with results posted, then the rest; newest registration first within each.
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingNCT07857226Phase 2
- Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNot yet recruitingNCT07795424Phase 2
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.RecruitingNCT07788196Phase 2
- Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian CancerNot yet recruitingNCT07779538Phase 3
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingNCT07772245Phase 2
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
- Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingNCT07739511Phase 1/2
- Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMDRecruitingNCT07694986Phase 2
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingNCT07578116Phase 3
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingNCT07565324Phase 2
- Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard TherapyRecruitingNCT07506057Phase 2
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingNCT07407920Phase 2
- Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerRecruitingNCT07402473Phase 2
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingNCT07366840Phase 2/3
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingNCT07332533Phase 2/3
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingNCT07193394Phase 2
- Identification of HER2-Positive Breast Cancer Molecular Characterization and SubtypesNot yet recruitingNCT07187752Not applicable
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2
- Asciminib in HER2+ Breast Cancer Brain MetastasesRecruitingNCT07136428Phase 1/2
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingNCT07102381Phase 2
- Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Not applicable
- Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer PatientsRecruitingNCT07062263Phase 3
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingNCT07007559Phase 2
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingNCT06998771Phase 2
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingNCT06881017Phase 2
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabRecruitingNCT06876714Phase 3
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
- TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal CancerRecruitingNCT06589830Phase 2
- The Sagittarius TrialRecruitingNCT06490536Phase 3
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingNCT06441890Phase 2
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
- Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJCNot yet recruitingNCT06439550Phase 2
- The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical StudyRecruitingNCT06254690Phase 2
- Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT06245356Phase 2
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).RecruitingNCT06217185Phase 4
- Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingNCT06162559Phase 1
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingNCT06123338Phase 2
- Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast CancerRecruitingNCT06035679Not applicable
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingNCT06016387Phase 2
- Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric CancerRecruitingNCT05975749Phase 2
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingNCT05800275Phase 2
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/3
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingNCT05760612Phase 3
- First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)RecruitingNCT05749900Phase 1/2
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2
- Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2
- Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line TherapyRecruitingNCT05640830Phase 1/2
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
- A Study for the Adjuvant Treatment of Breast CancerRecruitingNCT05420467Phase 4
- A Study for the Neoadjuvant Treatment of Breast CancerRecruitingNCT05420454Phase 4
- Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)Not yet recruitingNCT05388500Phase 3
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain MetastasisRecruitingNCT05376878Phase 4
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
- Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & PertuzumabRecruitingNCT05325632Phase 2
- Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingNCT05292742Phase 2
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingNCT05253651Phase 3
- Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingNCT05228951Phase 2
- SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaNot yet recruitingNCT05218148Phase 2
- TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal CancerRecruitingNCT05188313Phase 3
- CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerRecruitingNCT05187182Phase 1
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingNCT05020860Phase 2
- Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)Not yet recruitingNCT04922008Phase 2
- Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingNCT04886531Phase 2
- Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2
- Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGCRecruitingNCT04819971Phase 2
- Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)RecruitingNCT04817540Phase 2
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingNCT04680442Phase 2
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
- Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerRecruitingNCT04329065Phase 2
- Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerNot yet recruitingNCT04158856Phase 2
- Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaRecruitingNCT04150640Phase 2
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
- A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver MetastasisRecruitingNCT02102789Phase 3
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active, not recruitingNCT06136897Phase 2Results posted
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive, not recruitingNCT05113251Phase 3Results posted
- A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)Active, not recruitingNCT04721977Phase 2Results posted
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
- Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant TherapyTerminatedNCT04578106Phase 2Results posted
- A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative ResectionTerminatedNCT04510285Phase 2Results posted
- Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedNCT04499924Phase 2/3Results posted
- MARGetuximab Or Trastuzumab (MARGOT)Active, not recruitingNCT04425018Phase 2Results posted
- Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03CompletedNCT04109391Phase 3Results posted
- Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast CancerActive, not recruitingNCT03879577Phase 2Results posted
- Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerActive, not recruitingNCT03820141Phase 2Results posted
- Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal AdenocarcinomasCompletedNCT03783936Phase 2Results posted